Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, committed to transforming cancer care through the development of targeted therapies. The company leverages its proprietary drug development platforms to effectively tackle significant unmet medical needs in oncology, particularly in overcoming treatment resistance. With a diverse pipeline of therapeutic candidates targeting essential pathways for cancer cell survival, Oric is advancing its innovations through rigorous clinical trials, positioning itself as a potential leader in providing groundbreaking treatment options for patients facing challenging malignancies. Show more

Location: 240 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080, 2Nd Floor, South San Francisco, CA, 94080, USA | Website: https://www.oricpharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

970M

52 Wk Range

$3.90 - $14.93

Previous Close

$9.96

Open

$10.43

Volume

1,987,428

Day Range

$9.99 - $10.66

Enterprise Value

749.5M

Cash

49.67M

Avg Qtr Burn

-25.11M

Insider Ownership

6.71%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Enozertinib (ORIC-114) Details Cancer, 1L Non-small cell lung carcinoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enozertinib (ORIC-114) + amivantamab SC Details 1L Non-small cell lung carcinoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enozertinib (ORIC-114) Details Solid tumor/s, Advanced malignancies, Cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-944 + ERLEADA® (apalutamide) and NUBEQA® (darolutamide) Details Metastatic castration-resistant prostate cancer (mCRPC)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enozertinib (ORIC-114) Details 2L Non-small cell lung carcinoma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-533 Details Multiple myeloma, Cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-101 + Xtandi (enzalutamide) Details Prostate cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-101 and nab-paclitaxel Details Solid tumor/s, Muscle control disorder, Spasticity, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.